ClinicalTrials.gg
RecruitingNCT07112196VINCITUpdated Nov 2, 2026

Visugromab in Cachexia International Trial

A Phase 2/3 interventional study of Visugromab (CTL-002) and Placebo in Cancer-associated Cachexia, sponsored by CatalYm GmbH. Recruiting at 79 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by CatalYm GmbH · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.
Updated Nov 2, 2026First sites in Ireland and Netherlands5 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
518
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 95 studies in Cachexia with a site in United States — 9 open to participants now, 11 under way, 2 of them phase 3. Cachexia · United States.

Planned enrollment
3rd of 72
518 · median 51
Started
2026
with 2 others
Phase 2/3
2 of 95
2 open now
Primary completion
2029-12
later than 8 of 10 live
Registered
93rd of 95
by date

Among the 95 studies in Cachexia with a site in United States, this one is the 3rd largest by planned enrollment of the 72 interventional ones that give a count, is one of 3 that started in 2026, is one of 2 in phase 2/3, reaches primary completion later than 8 of the 10 other live ones, and was the 93rd registered.

Cachexia

331 studies on the registry are indexed under Cachexia; 74 are open to participants now.

Browse Cachexia studies →

Open to participants now

9 of the 95 studies in Cachexia with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 55 Cachexia studies recruiting now, 32 (58%) set no upper age limit and 14 (25%) stop at 75 or younger; 7 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 95 studies in Cachexia with a site in United States, or all of them as a file.
02

Study summary

A study of how well and safely a new drug called visugromab works in people with certain kinds of cancer (including lung and bowel cancer) and unintended weight loss known as cachexia. The main questions it aims to answer are:

  • Does visugromab help participants put weight back on and have a better appetite?
  • Does visugromab help participants move more and better?
  • What medical problems do participants have when taking visugromab? Researchers will compare visugromab to a placebo (a look-alike substance that contains no drug).

Participants will visit the hospital or clinic once every 4 weeks to receive visugromab or placebo via a drip into a vein and to undergo checkups and tests.

03

Conditions studied

  • Cancer-associated Cachexia

Keywords

  • Cachexia
  • Cancer
  • Weight loss
  • Wasting
  • Anorexia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Weight loss
  • Advanced cancer

Exclusion criteria

Exclusion Criteria:

  • Participation in another interventional clinical trial, receipt of any therapy or use of any investigational device within 4 weeks prior to screening and between screening and the first dose of investigational product
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
518 participants (estimated)

Study arms

  • Active comparator
    Visugromab low dose

    Drug: Visugromab (CTL-002)

  • Active comparator
    Visugromab medium dose

    Drug: Visugromab (CTL-002)

  • Active comparator
    Visugromab high dose

    Drug: Visugromab (CTL-002)

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change from baseline in body weight at 12 weeks

    Time frame: 12 weeks

  2. Change from baseline in appetite at 12 weeks

    Measured on the 5-item anorexia subscale of the Functional Assessment of Anorexia/Cachexia Therapy instrument (minimum score 0, maximum 20; higher is better outcome)

    Time frame: 12 weeks

07

Study locations

79 of 79 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2026 (actual). Primary completion is estimated for Dec 2029, 44 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2025
First posted
Aug 8, 2025
StartActual
Apr 16, 2026
Primary completionEst.
Dec 2029
CompletionEst.
Dec 2030
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
5 sites added — first sites in Ireland and Netherlands
Show 5 added (1 United States, 1 France, 1 Germany, 1 Ireland, 1 Netherlands)
  • Cleveland Clinic Weston Hospital · Weston, United States
  • AP-HP Hopital Cochin · Paris, France
  • Universitaetsmedizin der Johannes Gutenberg - Universitaet Mainz · Mainz, Germany
  • St Vincent's University Hospital · Dublin, Ireland
  • Dijklander Ziekenhuis - Locatie Hoorn · Hoorn, Netherlands
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    5 sites added — first sites in Ireland and Netherlands
    Show 5 added (1 United States, 1 France, 1 Germany, 1 Ireland, 1 Netherlands)
    • Cleveland Clinic Weston Hospital · Weston, United States
    • AP-HP Hopital Cochin · Paris, France
    • Universitaetsmedizin der Johannes Gutenberg - Universitaet Mainz · Mainz, Germany
    • St Vincent's University Hospital · Dublin, Ireland
    • Dijklander Ziekenhuis - Locatie Hoorn · Hoorn, Netherlands
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07112196
Lead sponsor
CatalYm GmbH
Responsible party
Sponsor
First posted
Aug 8, 2025
Start date
Apr 16, 2026
Primary completion
Dec 2029 (estimated)
Completion
Dec 2030 (estimated)
Last update
Nov 2, 2026

Study contacts

Trial Director
Contact
regulatory-006@catalym.com
49 8920006640

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Visugromab

Start the discussion